Dr. Jonathan Gabor is a specialist in general internal medicine with post-graduate subspecialty training and expertise in several areas of cardiometabolic disease including heart failure, hypertension, metabolic syndrome, atherosclerosis, dyslipidemia, obesity pharmacotherapy, non-alcoholic fatty liver disease, and obstructive sleep apnea. He is board-certified in obesity from the American Board of Obesity Medicine, a Specialist in Clinical Hypertension from the American Society of Hypertension, and a Specialist in Heart Failure from the European Society of Cardiology. He continues to participate in knowledge dissemination and guideline development, serving on subcommittees of the Canadian Heart Failure Society, the Canadian Cardiovascular Society, Obesity Canada, the U.S. National Lipid Association, the European Society of Cardiology, the advisory board of the U.S. Cardiometabolic Health Congress, and the guidelines development committee of Hypertension Canada. He is one of the authors of the national hypertension 2020 guidelines update, including the chapter on the diagnosis and management of resistant hypertension. He is member of the national scientific committee of Obesity Canada and the Chair of its Winnipeg chapter. Dr. Gabor is a representative of the Canadian NASH network, a national collaboration of health care professionals with an interest in advocacy, education, and clinical research in non-alcoholic fatty liver disease. Lastly, he is also a member of the scientific committee of the 2022 Canadian Cardiovascular Harmonized Guidelines Endeavour, with the mandate to harmonize and combine the numerous national guidelines including those pertaining to obesity, hypertension, diabetes, dyslipidemia, and heart failure.